Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648134 | 0.89 | TLR4 (0.44) | FYNTLR4ALDH1A1NPSR1CYP2C9 | |
| SCHEMBL12648342 | 0.87 | CYP1A2 (0.45) | TLR4ALDH1A1KMT2ACYP2C9MAPT | |
| SCHEMBL14867423 | 0.85 | CYP1A2 (0.44) | TLR4ALDH1A1KMT2AELANECYP1A2 | |
| SCHEMBL1766113 | 0.83 | NPSR1 (0.35) | ALDH1A1NPSR1KMT2AMAPTLMNA | |
| SCHEMBL15328544 | 0.74 | NPSR1 (0.38) | ALDH1A1NPSR1MAPT | |
| SCHEMBL19263350 | 0.74 | NPSR1 (0.33) | NPSR1 | |
| SCHEMBL18272605 | 0.74 | SMN1; SMN2 (0.39) | TLR4ALDH1A1 | |
| SCHEMBL12648140 | 0.73 | TLR4 (0.44) | TLR4ALDH1A1MAPTELANELMNA | |
| SCHEMBL10424086 | 0.73 | KMT2A (0.35) | TLR4NPSR1KMT2A | |
| SCHEMBL1177190 | 0.72 | FYN (0.41) | FYNHCAR2TLR4NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838881-B1 | ISOINDOLONE DERIVATIVES | ABBVIE INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9776990-B2 | Isoindolone derivatives | ABBVIE INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150111890-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. | 2015-04-23 | — | — | US | disclosed |
| EP-2850071-A1 | ISOINDOLONE DERIVATIVES | AbbVie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2838881-A1 | ISOINDOLONE DERIVATIVES | AbbVie Inc. (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013155695-A1 | ISOINDOLONE DERIVATIVES | ABBOTT LABORATORIES (US) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013158952-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281450-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111890-A1 | ISOINDOLONE DERIVATIVES | CYP11B1, HSD17B7, CYP4A11 | FYN 3663/4885HCAR2 1404/4885TLR4 1920/4885 |
| US-20130281450-A1 | ISOINDOLONE DERIVATIVES | CYP11B1, HSD17B7, CYP4A11 | FYN 3604/4885HCAR2 1455/4885TLR4 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.